Changing the way doctors are paid could save over $1 trillion in health care costs, but physicians can’t do it on their own. One of the ways health insurers can help is by joining together to facilitate payment reform, says a study by UnitedHealth Group.

“The stronger financial incentives stemming from a multipayer initiative are more likely to provide both the impetus and support that doctors and other providers need to make changes in their practice patterns, treatment protocols, and other key processes,” says United’s working paper, “Farewell to Fee-For-Service? A ‘Real World’ Strategy for Health Care Payment Reform.”

The paper cites government projections that annual health care spending will rise from $2.8 trillion to $4.8 trillion in the next 10 years.

“There is now widespread agreement that paying providers of health care on a fee-for-service basis is a key contributor to both our cost and quality problems,” the paper states.

The results are based on surveys of 400 primary care physicians and 600 specialists in October 2011 and June 2012. They were asked about current methods of payment, their use of tools such as electronic health records, and their interest and views about possible new payment methods (see “ACOs Called Key to Doc Payment Reform,”).

The study found that only 28 percent of doctors thought that physician practices in their communities were prepared to assume greater responsibility for managing patient care and to assume more financial risk — both seen as important elements of health care reform.

The new emphasis on providers means finding doctors who are leaders. In fact, as the paper says, the Government Accountability Office identified doctor leadership as the most important role “in promoting the adoption of interventions by their organizations, in winning acceptance among affected staff members for the changes those interventions entail, and in marshaling sufficient resources for the interventions to succeed.”

A joint health plan effort might work, but there might be drawbacks, including difficulty in reaching consensus, a process that might take a long time and result in a lowest-common-denominator approach to payment reform.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.